Equities

Alligator Bioscience AB

Alligator Bioscience AB

Actions
  • Price (EUR)0.1096
  • Today's Change0.003 / 2.62%
  • Shares traded10.00k
  • 1 Year change+217.68%
  • Beta--
Data delayed at least 15 minutes, as of Sep 23 2024 08:18 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of SEK
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments6697278
Total Receivables, Net4.521814
Total Inventory------
Prepaid expenses7.557.946.98
Other current assets, total--0.00--
Total current assets78123300
Property, plant & equipment, net202715
Goodwill, net------
Intangibles, net181818
Long term investments------
Note receivable - long term1.991.82--
Other long term assets----0.00
Total assets118170333
LIABILITIES
Accounts payable21139.37
Accrued expenses653923
Notes payable/short-term debt000
Current portion long-term debt/capital leases8.588.506.23
Other current liabilities, total3.823.808.79
Total current liabilities996547
Total long term debt7.52163.51
Total debt16259.74
Deferred income tax------
Minority interest------
Other liabilities, total--0.000
Total liabilities1078151
SHAREHOLDERS EQUITY
Common stock428988
Additional paid-in capital1,055912912
Retained earnings (accumulated deficit)(1086)(911)(718)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total--0.00--
Total equity1289282
Total liabilities & shareholders' equity118170333
Total common shares outstanding659365364
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.